These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 29385658)

  • 1. The role of glucocerebrosidase in Parkinson disease pathogenesis.
    Gegg ME; Schapira AHV
    FEBS J; 2018 Oct; 285(19):3591-3603. PubMed ID: 29385658
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Smith L; Schapira AHV
    Cells; 2022 Apr; 11(8):. PubMed ID: 35455941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains.
    Gegg ME; Burke D; Heales SJ; Cooper JM; Hardy J; Wood NW; Schapira AH
    Ann Neurol; 2012 Sep; 72(3):455-63. PubMed ID: 23034917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucocerebrosidase and Parkinson disease: Recent advances.
    Schapira AH
    Mol Cell Neurosci; 2015 May; 66(Pt A):37-42. PubMed ID: 25802027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between glucocerebrosidase mutations and Parkinson disease.
    Migdalska-Richards A; Schapira AH
    J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):77-90. PubMed ID: 26860875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucocerebrosidase-associated Parkinson disease: Pathogenic mechanisms and potential drug treatments.
    Gegg ME; Menozzi E; Schapira AHV
    Neurobiol Dis; 2022 May; 166():105663. PubMed ID: 35183702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease.
    Magalhaes J; Gegg ME; Migdalska-Richards A; Doherty MK; Whitfield PD; Schapira AH
    Hum Mol Genet; 2016 Aug; 25(16):3432-3445. PubMed ID: 27378698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucocerebrosidase deficiency promotes release of α-synuclein fibrils from cultured neurons.
    Gegg ME; Verona G; Schapira AHV
    Hum Mol Genet; 2020 Jun; 29(10):1716-1728. PubMed ID: 32391886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues.
    Menozzi E; Toffoli M; Schapira AHV
    Pharmacol Ther; 2023 Jun; 246():108419. PubMed ID: 37080432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
    Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
    J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroblasts from idiopathic Parkinson's disease exhibit deficiency of lysosomal glucocerebrosidase activity associated with reduced levels of the trafficking receptor LIMP2.
    Thomas R; Moloney EB; Macbain ZK; Hallett PJ; Isacson O
    Mol Brain; 2021 Jan; 14(1):16. PubMed ID: 33468204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease.
    Horowitz M; Braunstein H; Zimran A; Revel-Vilk S; Goker-Alpan O
    Adv Drug Deliv Rev; 2022 Aug; 187():114402. PubMed ID: 35764179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models.
    Sanchez-Martinez A; Beavan M; Gegg ME; Chau KY; Whitworth AJ; Schapira AH
    Sci Rep; 2016 Aug; 6():31380. PubMed ID: 27539639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondrial dysfunction associated with glucocerebrosidase deficiency.
    Gegg ME; Schapira AH
    Neurobiol Dis; 2016 Jun; 90():43-50. PubMed ID: 26388395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective loss of glucocerebrosidase activity in sporadic Parkinson's disease and dementia with Lewy bodies.
    Chiasserini D; Paciotti S; Eusebi P; Persichetti E; Tasegian A; Kurzawa-Akanbi M; Chinnery PF; Morris CM; Calabresi P; Parnetti L; Beccari T
    Mol Neurodegener; 2015 Mar; 10():15. PubMed ID: 25881142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucocerebrosidase mutations: A paradigm for neurodegeneration pathways.
    Vieira SRL; Schapira AHV
    Free Radic Biol Med; 2021 Nov; 175():42-55. PubMed ID: 34450264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing the Activity of Glucocerebrosidase as a Treatment for Parkinson Disease.
    Menozzi E; Schapira AHV
    CNS Drugs; 2020 Sep; 34(9):915-923. PubMed ID: 32607746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucocerebrosidase and parkinsonism: lessons to learn.
    Marković I; Kresojević N; Kostić VS
    J Neurol; 2016 May; 263(5):1033-1044. PubMed ID: 26995357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucocerebrosidase deficits in sporadic Parkinson disease.
    Murphy KE; Halliday GM
    Autophagy; 2014 Jul; 10(7):1350-1. PubMed ID: 24915553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson's disease and their targeted therapeutic approaches: a comprehensive review.
    Behl T; Kaur G; Fratila O; Buhas C; Judea-Pusta CT; Negrut N; Bustea C; Bungau S
    Transl Neurodegener; 2021 Jan; 10(1):4. PubMed ID: 33446243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.